EGFR and neoplasm: However, quantitative analysis in Wei et al’s study indicated that EGFR mutation ratios (amount of mutant EGFR:all EGFR present) were significantly lower in metastatic compared with primary tumour samples (Wilcoxon matched-pair test; P < 0.01), suggesting a more moderate mutation ratio concordance of 84 %.